Cencora, Inc. (COR) Form 10-Q — Aug 5, 2026

Key figures

Eps

$3.94 diluted (Q3, vs $3.52 prior year); $15.21 diluted (nine months, vs $9.70 prior year)

Revenue

$84.75 billion (Q3 FY2026); $249.04 billion (nine months FY2026)

Guidance

Expects approximately $900 million of capital expenditures in fiscal 2026; no key customer contracts scheduled to expire over the next twelve months

Net Income

$776.7 million total / $763.5 million attributable to Cencora (Q3); $2.97 billion total / $2.96 billion attributable (nine months)

Total Debt

$11.72 billion as of June 30, 2026 (vs ~$7.66 billion at September 30, 2025)

Debt Amount

$3.0 billion senior notes and $1.5 billion variable-rate term loans issued February 2026 to finance the OneOncology acquisition

Revenue Yoy

+5.1% (Q3); +4.8% (nine months)

Cash Position

$2.82 billion as of June 30, 2026

Interest Rate

5.650% on the $500 million 2056 Notes (effective yield 5.681%)

Maturity Date

February 2056 (2056 Notes)

Shares Outstanding

190827165

Glp1 sales q3

$2.3 billion, +25.5%

Dividend per share

$0.60 quarterly, +9% (November 2025)

Effective tax rate

22.1% (Q3); 21.6% (nine months)

Glp1 sales nine months

$5.2 billion, +19.7%

New buyback authorization

$2.0 billion (May 2026); $1,882.2 million remaining as of June 30, 2026

Revolving credit facility

Amended July 2026 to $7.0 billion, expiring July 2031

Opioid litigation liability

$4.2 billion payable over next 13 years; $396.2 million expected before June 30, 2027

Oneoncology cash consideration

$4,648.7 million

Oneoncology remeasurement gain

$1,086.6 million

Oneoncology total consideration

$7,387.1 million

Operating cash flow nine months

$1.7 billion vs $0.7 billion prior year

Impairment us consulting services

$249.5 million (including $165.7 million goodwill)

Price after filing

Close on the filing date to close N calendar days later (from $306.28). Historical, not a forecast.